Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
...Report of Positive Results with Innovative Pro-Healing Stent is Featur... ESC Congress 2007 ...VIENNA Austria Sept. 3 /- OrbusNeich today announcedth...Presented today by Robbert de Winter M.D. Ph.D. at the EuropeanSoc...
Date:9/3/2007
Report of Positive Results with Innovative Pro-Healing Stent is Featured at
ESC Congress 2007
VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced
that post-marketing data from patient subsets of a global registry support
the use of the company's Genous(TM) Bio-engineered R stent(TM) as an
alternative to drug-eluting stents.
Presented today by Robbert de Winter, M.D., Ph.D., at the European
Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from
OrbusNeich's e-HEALING registry show:
* For 296 diabetic patients at six months, the target lesion
revascularization (TLR) rate was 2%, which is much lower than was
anticipated
* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]
six months
* For 923 patients with statin use, the major adverse cardiac events
(MACE) rate at six months was 5.7%, while 116 patients without statin
use experienced a MACE rate of 6.9% over the same period
"This real-world data strengthen our belief that Genous is a very
promising alternative to drug-eluting stents," said de Winter, a
co-principal investigator of the study and director of the catheterization
laboratory at the Academic Medical Center in Amsterdam. "Genous appears to
have the same efficacy as drug-eluting stents but a better safety profile
with only minimal dual-antiplatelet therapy requirements. This is an
important finding in that physicians are becoming reluctant to burden their
patients with the cost and compliance issues associated with drug-eluting
stents and their extensive dual-antiplatelet therapy requirements."
OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United
States) prospective registry of patients treated with the Genous Bio-
engineered R stent in accordance with the instructions for use. The
protocol recommends that patients receive two weeks of statin treatment
prior t
'/>"/>
SOURCE OrbusNeich Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
One in Three Heart Attack Patients Have No Chest Pains
2.
Amphetamines Help Recovery of Stroke Patients
3.
Painkillers Do Not Shorten Dying Patients Lives
4.
Patients With Filariasis More Prone To HIV Infection5.
Glivec - New Hope For CMC Patients6.
Patient’s perception of health status helps in better recover7.
HIV infected patients can travel safely abroad8.
New vaccine helps allergy and asthma patients9.
Doctors operate upon patients in candlelight- latest from the quake scene10.
New vaccine helps allergy and asthma patients11.
Are cancer patients being taken for a ride?
(Date:11/22/2009)...hysician-scientists from Weill Cornell Medical Col...y prove to be a powerful target for the treatment ...ffects lymphocytes, or white blood cells. By explo...o powerfully suppress tumor formation in lab testi...e led to the design of a clinical trial that will ...
(Date:11/22/2009)...& Machine post You Tube video demonstrating th... Landover, MD (PRWEB) Novemb...in learning what a really rugged waterproof keyboa...ool Keyboard vs Washable Competitors Keyboard HD&r...ow the premium, Really Cool Keyboard from Man &am...
(Date:11/21/2009)... Milvia Lopez, by her attorney MICH...led suit, in Supreme Court, New York County, beari... while Ms. Lopez underwent a routine transesophage...AL , doctors used an HIV infected scope exposing h...ral hours after being discharged from the procedur...
(Date:11/21/2009)...vative medical apparel company launches men,s lab ... San Clemente, Calif. (PRWEB) November 21,...cal apparel, today announced the launch of its men... a leading international trade fair for the medica...naugurates its men,s collection with three varying...
(Date:11/20/2009)...ist Closer to Understanding Brain Wiring and Disea...re/ -- Dr. Jeremy Schmahmann, Professor of Neurolo...e Massachusetts General Hospital in Boston, on Thu...earch on the new field of study called "Connectivi..., Dr. Schmahmann is an award-winning leader in the...
Breaking Medicine News(10 mins):Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:Waterproof, Cleanable Computer Keyboard Video Comparison Now Available on You Tube 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2...ory for patient-centered medical home model, WASH... Collaborative (PCPCC) released the following stat...e bill, which includes a provision,for a $100 mill... medical home demonstration projects in Medicare w...
... 10 Omnicell, Inc.,(Nasdaq: OMCL ), a leading pr...ilities, will hold a conference call Monday, July ...nancial results., What: Omnicell second quart... Rob Seim, chief financial officer Where: ...
...fect developing brain,s ability to make neural con...News) -- Common underlying mechanisms that affect ...gly disparate gene mutations found in autistic peo...ople that appear to be tied to inherited mutations...
...mproves Kidney Care in America--Increased,Kidney C...fit, WASHINGTON, July 10 In response to the,pass...dney Care Partners,(KCP) -- an alliance of patient...nd kidney failure -- applauded the United,States S...
...wing is a,statement by Mark J. Feldman, DMD, Presi...ncement that 70 percent of the U.S. population now...me this very encouraging news from the Centers for...and,scientific study that community water fluorida...
...prove Genetic Healthcare and Educate Patients, SA... and,Iverson Genetic Diagnostics, Inc. today annou...personalized reports for individuals receiving,Ive... for Iverson customers, allowing physicians who wo...
Other Medicine News:Health News:Omnicell to Release Second Quarter 2008 Earnings Results on July 21 2Health News:Common Mechanisms May Contribute to Autism's Mutations 2Health News:Kidney Community Applauds Senate for Passage of End Stage Renal Disease (ESRD) Improvements 2Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 2Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 3(Date:11/20/2009)..., , FRANKLIN LAKES, N.J., Nov. 20 /PRNewswire...(NYSE: BDX ) today announced the completion of i...chigan-based company that develops and manufacture...orms. ,, In May 2009, BD and HandyLab announced...ercialize molecular assays on the HandyLab Jaguar(...
(Date:11/19/2009)..., , BIRMINGHAM, Ala., Nov. 19 /PRNewswire-F...q: BCRX ) today announced the pricing of a public...at $9.75 per share, resulting in gross proceeds of...red by BioCryst pursuant to an effective shelf reg...rities and Exchange Commission. BioCryst has also...
(Date:11/19/2009)..., , MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswir...aq: ALXA ) announced today that its corporate pre...ual Piper Jaffray Health Care Conference on Wednes...The presentation will be webcast from The New York... Thomas B. King, Alexza President and CEO. ,,...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Binghamton Research Group Develops New Cancer Treatment 5010 1Binghamton Research Group Develops New Cancer Treatment 5010 2Binghamton Research Group Develops New Cancer Treatment 5010 3Binghamton Research Group Develops New Cancer Treatment 5010 4HBV genotype B B3 and C C1 are the major genotypes in Indonesia 3F 57345 1Reactive oxygens role in metastasis 9946 1Reactive oxygens role in metastasis 9946 2...cal Studies Confirm Mechanism of Action and,Provid...16, 2007 /PRNewswire-FirstCall/ --,Sunesis Pharmac...rating SNS-032,s apoptotic activity in a multiple ...a poster session during,the Annual Meeting of the ... SNS-032, a selective and potent inhibitor of cycl...
...CR Annual Meeting, BLOOMFIELD, N.J., April 16, 200...oday announced that in vivo and in vitro,preclinic...ciation,for Cancer Research (AACR) Annual Meeting ...bits tumor growth of non-small cell,lung cancer (N...led "Increased apoptosis and reduced lactate,level...
Other Medicine Technology:Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting 2Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting 3Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 2Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 3...n advanced scientific formulation that provides po...ct Plus is based on the AREDS clinical trial, and ...g the role of lutein in eye health. Featuring low ...nt blend of antioxidant nutrients and delivers 15 ...
...is a scientifically advanced nutritional formulati...nd full body health. MacularProtect Complete is ba... research. It features a comprehensive multinutrie...ntioxidants, such as 10 mg of FloraGLO® lutein...
Oculair
Ocuvite® Eye Vitamins and Mineral Supplement
Medicine Products: